Tumor-penetrating polymersomes encapsulating a novel anthracycline for cancer treatment

Lorena Simón-Gracia & Valeria Sidorenko Ain Uustare, Ivan Ogibalov, Andrus Tasa, Olga Tshubrik, Tambet Teesalu.

Laboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14b, 50411 Tartu, Estonia Lorena.Simon.Gracia@ut.ee

Novel anticancer compounds and their precision delivery systems are actively developed to create potent and welltolerated anticancer therapeutics. Tumourpenetrating peptides (TPPs) can be used to increase the accumulation and penetration of nanocarriers in the tumour [1]. We encapsulated anthracycline, а novel Utorubicin (UTO), which is more toxic to cultured tumour cell lines than doxorubicin, in biocompatible polymeric nanovesicles (polymersomes, PS) functionalized with TPPs [2]. Nanoformulated UTO reduced the viability of cultured malignant cells and this effect was potentiated by functionalization with the TPP. Systemic peptide-guided PS showed preferential accumulation in triplenegative breast tumour xenografts implanted in mice (Fig. 2A), and enhanced the UTO accumulation in tumour. Moreover, in an experimental treatment of mice with peritoneal carcinomatosis, UTO-loaded PS decreased the tumour growth after systemic administration (Fig. 2B). Our studies show the potential application of our novel UTOloaded polymersomes in precision cancer therapy.

References

- [1] Teesalu et al. Frontiers in Oncology, 216 (2013),1
- [2] Simón-Gracia and Sidorenko et al. Angew. Chem. Int. Ed., 31 (2021), 17018

Figures




Figure 1: New anthracycline Utorubicin loaded in peptide-functionalized polymersomes for targeting solid tumours

